Gujarat Themis Biosyn Ltd
NSE: GUJTHEM BSE: 506879Pharma
Incorporated in 1981, Gujarat Themis Biosyn Ltd manufactures and sells finished Active Pharmaceutical Ingredients products by fermentation process[1]
₹356
52W: ₹225 — ₹479
PE 81.2 · Book ₹24.3 · +1365% vs bookMarket Cap₹3,879 Cr
Stock P/E81.2Price to Earnings
ROCE27.3%Return on Capital
ROE21.7%Return on Equity
Div. Yield0.18%Face Value ₹1
Strengths
- +Company has a good return on equity (ROE) track record: 3 Years ROE 31.5%
- +Company's working capital requirements have reduced from 62.3 days to 45.6 days
Weaknesses
- −Stock is trading at 14.3 times its book value
- −Company might be capitalizing the interest cost
- −Debtor days have increased from 59.2 to 75.6 days.
- −Promoter holding has decreased over last 3 years: -4.13%
Shareholding Pattern
Promoters70.86%
FIIs1.8%
DIIs1.17%
Public26.15%
| Category | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 70.87% | 70.87% | 70.87% | 70.87% | 70.87% | 70.87% | 70.87% | 70.86%▼0.0 |
| FIIs | 1.44% | 1.49%▲0.1 | 1.42%▼0.1 | 1.91%▲0.5 | 2.51%▲0.6 | 2.95%▲0.4 | 1.96%▼1.0 | 1.8%▼0.2 |
| DIIs | 1.18% | 1.17%▼0.0 | 1.17% | 1.17% | 1.17% | 1.17% | 1.17% | 1.17% |
| Public | 26.52% | 26.47%▼0.1 | 26.55%▲0.1 | 26.05%▼0.5 | 25.44%▼0.6 | 25.01%▼0.4 | 26%▲1.0 | 26.15%▲0.1 |
Financial Statements
| Metric | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 40 | 39 | 42 | 39 | 35 | 40 | 38 | 36 | 42 | 43 |
| Expenses | 23 | 21 | 21 | 20 | 19 | 21 | 22 | 22 | 21 | 22 |
| Operating Profit | 17 | 18 | 21 | 19 | 15 | 19 | 16 | 14 | 21 | 21 |
| OPM % | 42% | 46% | 50% | 48% | 44% | 48% | 42% | 39% | 49% | 49% |
| Net Profit | 13 | 13 | 16 | 13 | 11 | 13 | 12 | 9 | 14 | 12 |
| EPS ₹ | 1.15 | 1.19 | 1.46 | 1.21 | 0.97 | 1.19 | 1.1 | 0.83 | 1.31 | 1.14 |
AI Insights
Revenue Trend
TTM revenue at ₹159Cr, up 5.3% YoY. OPM at 45%.
Debt Position
Borrowings at ₹71Cr. Debt-to-equity ratio: 0.28x. Healthy balance sheet.
Capex Cycle
CWIP at ₹132Cr (81% of fixed assets). Significant capex underway — growth runway building.
Institutional Flow
DIIs: 1.17% (+1.14pp change). FIIs: 1.8% (+1.79pp change). Promoters hold 70.86%.
Margin & Efficiency
ROCE declining from 208% (Mar 2014) to 27% (Mar 2025). Working capital days: 46.
Valuation
PE 81.2x with 27.3% ROCE. Price is 1365% above book value of ₹24.3. Dividend yield: 0.18%.
Recent Announcements
- Announcement under Regulation 30 (LODR)-Newspaper Publication 6 May - Please refer to the copy of Newspaper Publication of Postal Ballot Notice.
- Shareholder Meeting / Postal Ballot-Notice of Postal Ballot 5 May - Postal ballot seeks Rs 3,500 crore borrowing and investment limits; e-voting runs May 6-June 4, 2026.
- Announcement under Regulation 30 (LODR)-Press Release / Media Release 23 Apr - GTBL to acquire Sanofi's 13-product anti-TB/anti-infective portfolio for EUR 158 million, expected to close by Q3FY27.
- Announcement under Regulation 30 (LODR)-Investor Presentation 23 Apr
- Announcement under Regulation 30 (LODR)-Acquisition 23 Apr - GTBL signs €158 million asset purchase agreement to acquire 13 branded generic products from Sanofi.
- Financial Year 2025 from bse
- Financial Year 2024 from bse
- Financial Year 2023 from bse